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De Novo Loss-of-Function Mutations in SETD5, Encoding a
Methyltransferase in a 3p25 Microdeletion Syndrome
Critical Region, Cause Intellectual Disability
Detelina Grozeva,1 Keren Carss,2 Olivera Spasic-Boskovic,1 Michael J. Parker,3 Hayley Archer,4
Helen V. Firth,5 Soo-Mi Park,5 Natalie Canham,6 Susan E. Holder,6 Meredith Wilson,7 Anna Hackett,8
Michael Field,9 James A.B. Floyd,2,10 UK10K Consortium,2 Matthew Hurles,2 and F. Lucy Raymond1,*
To identify further Mendelian causes of intellectual disability (ID), we screened a cohort of 996 individuals with ID for variants in 565
known or candidate genes by using a targeted next-generation sequencing approach. Seven loss-of-function (LoF) mutations—four
nonsense (c.1195A>T [p.Lys399*], c.1333C>T [p.Arg445*], c.1866C>G [p.Tyr622*], and c.3001C>T [p.Arg1001*]) and three frameshift
(c.2177_2178del [p.Thr726Asnfs*39], c.3771dup [p.Ser1258Glufs*65], and c.3856del [p.Ser1286Leufs*84])—were identified in SETD5, a
gene predicted to encode a methyltransferase. All mutations were compatible with de novo dominant inheritance. The affected
individuals had moderate to severe ID with additional variable features of brachycephaly; a prominent high forehead with synophrys
or striking full and broad eyebrows; a long, thin, and tubular nose; long, narrow upslanting palpebral fissures; and large, fleshy low-set
ears. Skeletal anomalies, including significant leg-length discrepancy, were a frequent finding in two individuals. Congenital heart
defects, inguinal hernia, or hypospadias were also reported. Behavioral problems, including obsessive-compulsive disorder, hand
flapping with ritualized behavior, and autism, were prominent features. SETD5 lies within the critical interval for 3p25 microdeletion
syndrome. The individuals with SETD5 mutations showed phenotypic similarity to those previously reported with a deletion in
3p25, and thus loss of SETD5 might be sufficient to account for many of the clinical features observed in this condition. Our findings
add to the growing evidence that mutations in genes encodingmethyltransferases regulating histone modification are important causes
of ID. This analysis provides sufficient evidence that rare de novo LoF mutations in SETD5 are a relatively frequent (0.7%) cause of ID.The identification of over 100 rare but highly penetrant X
chromosome genes in which mutations cause intellectual
disability (ID) supports the hypothesis that the human
genome contains more than 2,000 genes critical to normal
intellectual development.1 When the causative variants
are rare andwhen candidate genes are numerous, the inter-
pretation of a single novel variant in a gene not previously
associated with disease is challenging. The recent analysis
by Piton et al. looked at evidence of pathogenicity for
many of the X chromosome genes in which mutations
are reported to cause ID and elegantly demonstrated how
previously published evidence of disease causality needs
careful review in the light of sequence data of large popu-
lation sets.2 As our knowledge of rare variants in the
normal population increases, there is a need to establish
increasingly stringent criteria to evaluate whether a
disease-causing variant has been identified to ensure the
accurate translation of new knowledge into safe clinical
practice.3
In order to identify further Mendelian causes of ID, we
screened 996 ID-affected individuals for variants in previ-
ously associated genes and candidate genes for ID on the
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priate ethical approval was obtained (research ethics
committee reference 03/0/014), and parents or guardians
provided written informed consent. We performed DNA
sequence analysis by using next-generation sequencing
methods to investigate the coding sequence of 565 genes
(Table S1, available online) from 996 individuals with
moderate to severe ID (all samples met DNA quality
metrics). This was a subset of a large replication study of
seven rare diseases and comprised a total of 2,812 individ-
uals who were investigated within the UK10K study. The
phenotypes studied were congenital heart disease, ciliop-
athy, coloboma, ID, neuromuscular disease, severe insulin
resistance, and congenital thyroid disease; internal tech-
nical control samples were also included for comparison.
The GenomiPhi V2 DNA Amplification Kit (GE Health-
care) was used for whole-genome amplification of the
DNA used for sequence analysis with the use of 1 ml of
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Figure 1. Families Affected by SETD5 Mutations
The pedigree for each family is shown at the top. Sanger sequencing electropherograms of the mutations are shown below the pedigrees.
An arrow indicates the position of the mutation. The genomic coordinates are according to the GRCh37/hg19 human reference
sequence. Abbreviations are as follows: NA, not available; WT, wild-type; and mut, mutation. Asterisks indicate that the Sanger
sequencing illustration is of the reverse strand.Genome Browser) of 1,189 genes, of which 565 were ID-
related candidate or known genes. Target enrichment
and amplification were performed with the HaloPlex
Target Enrichment Kit (Agilent Technologies) according
to the manufacturer’s instructions. The Illumina HiSeq
2000 platform was used to sequence the exons from the
targeted regions. Reads were aligned to the reference
genome (GRCh37/hg19) with the Burrows-Wheeler
Aligner, and single-nucleotide variants (SNVs) and small
indels were identified with SAMtools.4,5 For each sample,
variants sites (SNVs and indels) were called with the
Genome Analysis Toolkit Unified Genotyper.6 The calls
were then annotated with vcf-annotate (VCFtools).7 Func-
tional annotations were added with the Ensembl Variant
Effect Predictor v.2.8 against Ensembl 70.8 Standard
sequence quality-control criteria were applied to the called
variants: variants with a Phred-scaled quality score > 40
and a mapping quality score > 50 were investigated
further. The Integrative Genomics Viewer was used for
visually inspecting the underlying sequencing data.9
In addition, only rare variants with a minor allele
frequency < 1% in all of the following data sets were
considered for downstream analyses: 1000 Genomes, the
UK10K twins cohort, the NHLBI Exome Sequencing
Project (ESP), a cohort of 2,172 individuals from whom
whole exomes were sequenced at the same laboratory
(UK10K), and the UK10K rare replication cohort itself
(including all phenotypes). Furthermore, only putativeThe Amloss-of-function (LoF) variants (nonsense, frameshift, and
essential splice-site variants) were analyzed.
We selected the top ten genes with the highest number
of rare LoF variants present at frequencies < 1%
(Table S2). We then prioritized the genes for more detailed
follow-up on the basis of the following information: (1)
the number of different independent LoF variants identi-
fied in this cohort, (2) the presence of these variants in a
candidate gene, and (3) the paucity of rare LoF variants
in the candidate genes in controls according to frequencies
in the NHLBI ESP. On the basis of the above, SET-
containing-domain 5 (SETD5) was selected for further
investigation.
Seven independent LoF variants were identified within
the coding sequence of SETD5 in the ID cohort (Figure 1).
All seven variants were observed only once within the
whole UK10K replication cohort of 2,812 individuals
with rare disease. The total number of SETD5 haplotypes
sequenced was 5,624, which represents 1,992 alleles from
individuals with ID and 3,632 alleles from individuals
with other rare diseases not usually associated with
ID. None of these seven LoF variants have been
reported in PubMed, ClinVar, HGMD, dbSNP, or 1000
Genomes, and none were identified in the NHLBI ESP,
where coverage of the respective exons was available
for >4,000 European American individuals. Because
none of the individuals within the cohorts contributing
to the current data deposited in the NHLBI ESP wereerican Journal of Human Genetics 94, 618–624, April 3, 2014 619
described as having intellectual impairment, this was
used as an additional independent control set. The seven
LoF variants within SETD5 (CCDS46741.1, RefSeq
accession number NM_001080517.1) and their corre-
sponding protein truncations (RefSeq NP_001073986.1)
are the following: c.1195A>T (p.Lys399*), c.1333C>T
(p.Arg445*), c.1866C>G (p.Tyr622*), c.2177_2178del
(p.Thr726Asnfs*39), c.3001C>T (p.Arg1001*), c.3771dup
(p.Ser1258Glufs*65), and c.3856del (p.Ser1286Leufs*84)
(Figure 1).
We confirmed all of the variants by Sanger sequence
analysis by using stored nonamplified genomic DNA
from the probands and performed familial segregation
analysis to test a de novo hypothesis of disease (Figure 1).
For 5/7, we were able to establish molecular evidence of a
de novo variant in the proband. For the two families for
which a paternal sample was unavailable, the variant was
absent from thematernal sample and both parents were re-
ported clinically to have normal intellect, suggesting that
de novo inheritance was the most likely cause of disease
in these families. In one of the families (family 2) with
no paternal sample available, a sibling with a mild intellec-
tual impairment was found not to carry the mutation. The
number of de novo LoF variants expected to occur by
chance in SETD5 in a cohort of this size was calculated
with the use of the known exomemutation rate,10 the pro-
portion of variants expected to be LoF,11 and the length of
the coding sequence of SETD5 (4,329 bp). We compared
this number to the observed number (five) of molecularly
confirmed de novo LoF variants in SETD5 in our cohort
and found that the probability that they occurred indepen-
dently by chance was extremely low (p ¼ 5.253 109, cor-
rected for multiple testing). These results indicate that rare
LoF mutations in SETD5 are a likely cause of ID.
The CCDS46741.1 transcript of the coding sequence of
SETD5 is 4,329 bp long and encodes a protein of 1,442
amino acids. In this transcript, we found only one LoF
variant listed in public databases: a 4 bp polymorphic indel
(c.4277_4280del [p.Arg1426Profs*82]) with genomic posi-
tion chr3: 9,517,722. This LoF variant is located within the
terminal 16 amino acids of the protein and is reported in
38/3,904 European American adults (from the NHLBI
ESP). The seven SETD5 LoF variants present in the ID
cohort are all within the CCDS46741.1 sequence and
contribute to the major consensus transcript. The muta-
tions are all located upstream of the single polymorphic
LoF variant reported in the NHLBI ESP at the 30 end of
the gene. We then performed further analysis of the DNA
sequence from the affected individuals to identify whether
there were other more plausible variants that could
account for disease. In 6/7 individuals, we did not identify
further rare LoF or missense variants in any of the interro-
gated known genes in which mutations cause syndromic
or nonsyndromic ID, nor were there rare LoF variants in
candidate genes (565 genes in total). In the family 2
proband, we did identify an essential splice-site variant
(c.2914þ1G>A, genomic position chr3: 433,481, RefSeq620 The American Journal of Human Genetics 94, 618–624, April 3, 2NM_006614.3) in CHL1 (MIM 607416), a candidate gene
not previously associated with ID. This variant was
only present in the proband and was absent in the
mother and mildly affected brother. In addition, in the
family 2 proband, we observed a single missense variant
(c.179A>G, RefSeq NM_004595.4) in SMS (MIM 300105),
an X-linked gene in which mutations are reported to cause
ID (Snyder-Robinson syndrome [MIM 309583]) in males.
The variant was present in the unaffected mother and
mildly impaired brother of the proband. The residue is
not well conserved throughout evolution and is not
located within a conserved domain of the protein. We
concluded that this was not likely to be the primary cause
of disease in the family. Furthermore, the phenotype of the
mildly affected brother was not in keeping with Snyder-
Robinson syndrome. Thus, it is uncertain whether this
variant makes any additional contribution to the pheno-
type. The presence of the SETD5 variant in the proband
and the absence of the variant in the younger brother are
compatible with the more severe clinical features in the
older brother. The additional contribution of the CHL1
variant in the proband remains uncertain.
On the basis of the genotypic similarity of the seven
affected individuals, the clinical phenotype of each indi-
vidual was collated from the recruiting physicians, who
were blinded to the genotype for minimizing clinical bias
in reporting (Figure 2). One family declined permission
to publish photographs but permitted review by S.E.H.
and F.L.R. Although the clinical features were variable, a
number of common features other than ID included a
similar facial morphology comprising brachycephaly and
a prominent high forehead with striking eyebrows
described as full, broad, straight, or with synophrys. The
nose morphology was long, thin, and tubular. The
morphology around the eyes was similar with long,
narrow, and upslanting palpebral fissures; in addition,
mild ptosis, unilateral amblyopia, nystagmus, and stra-
bismus were described in single individuals. Ears tended
to be large with fleshy lobes, long, and low set; one indivi-
dual had a preauricular pit. The facial features of individual
2 (Figure 2) were slightly coarser than those of the other six
individuals, which might reflect the additional sequence
variants present. Feeding problems, particularly difficulties
with swallowing and chewing, were noted by several
families and physicians. Two children had congenital
heart defects; one had a mitral valve prolapse, and the
other had a ventricular septal defect with a patent ductus
arteriosus (Table 1 and Table S3). Four of the seven children
had either an inguinal hernia or hypospadias repaired at a
young age. Also, 4/7 children had skeletal abnormalities
that required varying degrees of intervention. Thoracic
scoliosis, kyphosis, and lordosis were reported, and two
children had a significant leg-length discrepancy (one of
them also had talipes and hypoplasia of the left calf and
required surgery). All children had intellectual impair-
ment, although all were able to talk and communicate
their needs. Speech, language, and motor developmental014
Figure 2. Facial Appearance of the Individuals with SETD5 Mutations
Columns numbered 1–6 correspond to families 1–6, respectively, in Figure 1. Photographs from family 7 were unavailable for
publication.delay were noted in all individuals. Behavioral problems
were a prominent feature of several of the children (5/7)
and ranged from obsessive-compulsive disorder to hand
flapping with ritualized behavior to features of autism.
Involuntary movements and an exaggerated startle
response were noted in several individuals, although in
none were these a sustained feature over time. Older
children had required special schooling because of their
ID and behavioral problems, although some attended
mainstream school at a young age but required educational
statements and extra support. Growth parameters were
within the normal range in all children, none had micro-
cephaly or seizures, and all were born without antenatal
or postnatal difficulties. Brain MRI was normal in one
individual and was not performed in the remaining six
individuals.
Although multiple LoF variants in SETD5 have not
been described previously in PubMed, this gene is one
of three genes—THUMPD3, SETD5, and THUMPD3-AS1
(a non-protein-coding gene)—within the critical region
for 3p25 microdeletion syndrome.12 Distal haploinsuffi-
ciency of chromosomal region 3p25 has long been associ-
ated with a clinical syndrome characterized by ID, low
birth weight, microcephaly, telecanthus, ptosis, micro-
gnathia, cleft palate, and congenital heart disease.
Initially, the critical interval that defined the microdele-The Amtion syndrome was a 4.3 Mb region that was both large
and gene dense.13 It was not clear whether deletion of a
single dosage-sensitive gene within this region was suffi-
cient to cause the syndrome or whether the phenotype
was a composite of multiple gene losses. Defining the
minimum common overlap of deletions in multiple
individuals has reduced the critical region for 3p25
microdeletion syndrome to three genes within a 124 kb
interval.12 The individuals with the smaller deletion
within 3p25 have been reported to have a common
phenotype of ID, hypotonia, a depressed nasal bridge,
and a long philtrum. The presence of congenital heart
disease and cleft palate is a more variable feature. Addi-
tional features also seen in the individuals reported with
the smallest 3p25 microdeletion include synophrys,
microcephaly, ptosis, abnormal palpebral fissures, post-
axial polydactyly, scoliosis, cleft palate, gastrointestinal
anomalies, and seizures.12,14–16 The similarity between
these individuals with haploinsufficiency of 3p25 and
the individuals reported here to have SETD5 truncating
mutations is of note (Table 1). We suggest that similar
to EHMT1 mutations in 9q34 for Kleefstra syndrome
(MIM 610253) and KANSL1 mutations in 17q21 for
Koolen-de Vries syndrome (MIM 610443), LoF mutations
in SETD5 might be sufficient to cause many of the fea-
tures of 3p25 microdeletion syndrome.erican Journal of Human Genetics 94, 618–624, April 3, 2014 621
Table 1. Clinical Features of the Individuals with SETD5Mutations
and Comparison to Individuals with 3p25 Microdeletion Syndrome
Clinical Features
Individuals with
SETD5 LoF
Mutations (n ¼ 7)
Individuals with
a 3p25 Deletion
(n ¼ 4)
Intellectual disability 7 4
Language delay and/
or stammer
6 NA
Ritualized behavior
and/or autism
5 NA
Seizures 0 2
Low birth weight and/
or growth retardation
0 2
Microcephaly 0 2
Brachycephaly 3 NA
Low-set and/or
malformed ears
5 3
Synophrys and/or
abnormal eyebrows
5 1
Hypertelorism 0 1
Ptosis 1 2
Upslanting or
downslanting
palpebral fissures
6 1
Depressed nasal bridge 3 3
Abnormal nasal shape 7 NA
Long, smooth, and/or
prominent philtrum
5 3
Thin upper lip 5 NA
Micrognathia 3 NA
Cleft palate 0 1
Postaxial polydactyly 1 1
Scoliosis or kyphosis 4 1
Leg-length discrepancy 2 NA
Feeding difficulties 5 NA
Congenital heart
defects
2 2
Gastrointestinal and/
or abdominal-wall
anomalies
5 1
Data for the 3p25 deletion were adapted from Kellogg et al.12 The following
abbreviations are used: LoF, loss of function; and NA, not available.Further evidence of the potential pathogenicity of muta-
tions in SETD5 is the observation of a single de novo LoF
variant in an ID cohort and of de novo missense variants
in two autism cohorts, although additional detailed
phenotypic data have not been reported.10,17,18
SETD5 is a methyltransferase on the basis of sequence
homology to other SET domain proteins.19 It is highly
conserved throughout mammalian species, suggesting
that it is functionally important, although little is
known yet of its specific role. SETD5 is ubiquitously622 The American Journal of Human Genetics 94, 618–624, April 3, 2expressed, and especially high levels of SETD5 expression
have been noted in the brain.20 On the basis of the
other family members of this gene group, SETD5 is
likely to be important in the control of histone modi-
fication of DNA and to act as a regulator of trans-
cription. Genes encoding methyltransferases specifi-
cally and genes encoding histone modifiers in general
are increasingly recognized to have a major contribution
to the phenotype of ID.21 Genes encoding histone modi-
fiers include MECP2 (MIM 300005), EHMT1 (MIM
607001), NSD1 (MIM 606681), KMT2D (MIM 602113),
KDM6A (MIM 300128), and KDM5C (MIM 314690).22–28
These genes are all dosage sensitive, and haploin-
sufficiency alone is recognized to be sufficient to cause
disease.21
Here, we present an analysis of children and young
adults who were recruited to the Genetics of Learning
Disability study with moderate to severe ID as the pre-
dominant clinical phenotype. This analysis provides
sufficient evidence that loss of function of SETD5 is a rela-
tively frequent cause of ID and occurs as a rare de novo
mutational event. The high number of LoF mutations in
this cohort (7/996 [0.7%]) suggests that SETD5mutations,
with a prevalence comparable to that of mutations in
ARID1B,29 might be one of the more common causes of
ID. The affected individuals showed phenotypic similarity
to those previously reported with a deletion in the critical
region of 3p25. Prior to mutation analysis, the clinical
features alone were not sufficient or consistent for
clinicians to delineate this syndrome. In none of the
individuals we report was a 3p25 microdeletion syndrome
clinically suspected. Genotype-driven syndrome recogni-
tion is likely to be increasingly used in the future as
more subtle phenotypes emerge. This, however, poses
concerns of overinterpreting the phenotypic features
and the need for large data sets for distinguishing rare
pertinent phenotypic associations from rare incidental
findings.Supplemental Data
Supplemental Data include three tables and can be foundwith this
article online at http://www.cell.com/ajhg.Acknowledgments
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